Brief: Galapagos Q1 Revenue Up 31% To EUR 178.9 Mln

Lakefront Biotherapeutics NV

05/05/2023 07:03

May 5 (Reuters) - Galapagos NV  GLPG.AS :
    * ANNOUNCED ON THURSDAY FIRST QUARTER 2023 FINANCIAL RESULTS
    * Q1 REVENUE EUR 178.9 MILLION UP +31%
    * Q1 EBIT EUR 22 MILLION VS LOSS 21.1 MLN IN 2022
    * QTRLY EARNINGS PER SHARE €0.4
    * OUTLOOK: REITERATE OUR FULL YEAR 2023 CASH BURN GUIDANCE
IN THE
RANGE OF EUR 380 MLN AND EUR 420 MLN
    * ON TRACK TO START THE PHASE 2 GALACELA STUDY IN PATIENTS
WITH
SLE LATER THIS YEAR
    * OUTLOOK 2023: EXPECT TO EXPAND OUR POINT-OF-CARE NETWORK
THROUGHOUT THE YEAR AND TO SUBMIT AN INVESTIGATIONAL NEW DRUG
APPLICATION IN THE US TO START CLINICAL DEVELOPMENT WITH OUR
CD19 CAR-T CANDIDATE LATER THIS YEAR
    * OUTLOOK 2023: AIM TO EXPAND OUR CAR-T PORTFOLIO WITH THE
START
OF THE PHASE 1/2 PAPILIO-1 STUDY IN EUROPE WITH BCMA CAR-T
CANDIDATE, GLPG5301, IN PATIENTS WITH MULTIPLE MYELOMA

Source text for Eikon:  ID:nGNX5wMBlY 
Further company coverage:  GLPG.AS 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))